Rafael Holdings' Trappsol Misses Primary Endpoint, NDA Still Q4

Rafael Holdings, Inc. (NYSE: RFL) announced on 30 September 2026 that its Cyclo Therapeutics subsidiary's pivotal Phase 3 TransportNPC study of Trappsol Cyclo in Niemann-Pick Disease Type C missed its primary endpoint, showing a 64% slowing of disease progression that fell short of statistical significance (p=0.19). A prespecified subgroup of patients on background miglustat and/or leucine, roughly 83% of the 94 enrolled, reached p=0.046. The company said it remains on track to submit an NDA in the fourth quarter of 2026.

Context — Why the NPC Readout Matters Now

The study is the largest controlled trial ever run in NPC, a rare, fatal and progressive genetic disorder with no approved disease-modifying therapy in the United States. That framing comes from the company's own chief medical officer, Dr. Karen Mullen, who called it "the most comprehensive trial in NPC conducted to date." The bar for a rare-disease filing is partly set by unmet need, and NPC sits at the extreme end of that spectrum.

The report anchors the result against two prior Trappsol Cyclo trials run across roughly a decade of development. Dr. Caroline Hastings of UCSF Benioff Children's Hospital Oakland said the findings align with those earlier studies. That consistency argument is central to how the company intends to present the dataset to regulators.

The catalyst chain runs from the pre-NDA meeting already held with the FDA, through the topline readout now disclosed, to a planned fourth-quarter submission. The company's prior guidance of a Q4 2026 NDA was unchanged by the miss on the primary endpoint.

Macro conditions are not the driver here. This is a single-asset binary event for a small-cap biotech, and the relevant backdrop is regulatory rather than rate-sensitive.

What changed is that investors now have the actual numbers rather than the expectation of them. The primary endpoint failed; the prespecified analysis succeeded; the survival analysis pointed the same direction. Each of those facts carries different weight for the FDA.

Data — What the Numbers Show

The primary endpoint measured change in the 4-domain NPC Clinical Severity Scale at Week 96. Trappsol Cyclo showed an LS mean change from baseline of 0.46 points versus 1.28 for placebo, a difference of −0.81 points (95% CI −2.04 to 0.41; p=0.19). The confidence interval crosses zero, which is why the company described the effect as directionally favorable rather than significant.

In the prespecified subgroup on background miglustat and/or leucine (n=78), the LS mean change was 0.46 versus 1.57, a difference of −1.11 points (95% CI −2.19 to −0.02; p=0.046). The upper bound of that interval sits just below zero.

Measure	Trappsol Cyclo	Placebo	Difference
Primary, 4DNPCSS change	0.46	1.28	−0.81 (p=0.19)
Prespecified subgroup	0.46	1.57	−1.11 (p=0.046)

Safety was broadly in line with prior studies. Treatment-emergent adverse events were 93.8% on drug versus 100.0% on placebo. Serious TEAEs ran 35.9% versus 16.7%, but those considered treatment-related were similar at 3.1% and 3.3%. One treatment-related case of bilateral deafness was severe; no TEAE led to death.

Analysis — What It Means for Markets and Tickers

For Rafael Holdings (RFL), the equity story now rests on whether the FDA accepts a filing built on a missed primary endpoint supported by a prespecified subgroup and an external-control survival analysis. The company did not disclose the trial's pre-specified alpha-spending plan or whether the subgroup was powered for the endpoint, so the regulatory weight of the p=0.046 result is unresolved.

The survival analysis is the more striking figure. In a comparison against matched external controls from the International Niemann-Pick Disease Registry (n=93), treatment with Trappsol Cyclo (n=41) was associated with an 85% reduction in mortality risk (HR=0.154; 95% CI 0.025–0.950; p=0.044). An expanded historical control analysis (n=133) showed a 94% reduction (HR=0.057; 95% CI 0.011–0.306; p=0.0008).

External-control designs draw scrutiny because the comparator is not randomized. The company's own forward-looking language concedes the topline data, complete dataset and survival analysis remain subject to full analysis and FDA review.

The readout is a negative for sentiment on single-asset rare-disease biotechs generally, since it reinforces that even well-run pivotal trials in heterogeneous diseases can miss. It is comparatively neutral for large-cap pharma, where NPC is not a commercial priority.

Positioning is likely binary: holders of RFL are underwriting the NDA acceptance probability, while short interest would build on the primary-endpoint failure if the subgroup argument is judged weak. Flow will follow the FDA's filing decision, not the topline print.

Outlook — What to Watch Next

The single scheduled catalyst is the NDA submission in the fourth quarter of 2026, which the company reaffirmed. Before that, the full dataset and overall survival analysis are to be finalized, and the company plans to present complete results at an upcoming medical meeting. No date for that meeting was disclosed.

Investors will also watch whether the FDA accepts the filing for review, a step the company's risk factors explicitly flag as uncertain. Acceptance would reset the timeline toward a decision date; a refusal-to-file would remove the near-term catalyst entirely.

No price levels are cited in the report, so there are no technical thresholds to track. The relevant binary is regulatory, not chart-based.

Frequently Asked Questions

What does the TransportNPC miss mean for retail investors in RFL?

It means the pivotal trial did not clear its primary endpoint, so the bull case now depends on the prespecified subgroup and the external-control survival data rather than the topline result. The company still targets a Q4 2026 NDA filing, but the FDA's acceptance of that filing is uncertain and is flagged in the company's own risk disclosures.

Why did the prespecified analysis reach significance when the primary endpoint did not?

The prespecified analysis excluded patients not on background miglustat and/or leucine, leaving 78 of 94 patients. That narrower group showed a larger placebo decline (1.57 points versus 1.28), which widened the treatment difference to −1.11 points and pushed the confidence interval just below zero. The company did not disclose whether the subgroup was powered for this endpoint.

What happens next for Rafael Holdings and Trappsol Cyclo?

The company plans to submit an NDA in the fourth quarter of 2026, consistent with prior guidance set after a pre-NDA meeting with the FDA. The full dataset and overall survival analysis remain subject to final analysis and regulatory review, and the company intends to present complete results at a future medical meeting without giving a date.

Bottom Line

Rafael Holdings missed its primary endpoint but kept its Q4 2026 NDA plan alive on a prespecified subgroup win.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.